Publikationen in Zusammenarbeit mit Forschern von Dana–Farber Cancer Institute (19)

2023

  1. Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100

    Gynecologic Oncology, Vol. 178, pp. 119-129

  2. Overall Survival with Maintenance Olaparib at a 7-Year Follow-Up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

    Journal of Clinical Oncology, Vol. 41, Núm. 3, pp. 609-617

  3. Overall Survival with Maintenance Olaparib at a 7-Year Follow-up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

    Obstetrical and Gynecological Survey

  4. Safety and management of niraparib monotherapy in ovarian cancer clinical trials

    International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 971-981

2022

  1. EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study)

    Future oncology (London, England), Vol. 18, Núm. 31, pp. 3481-3492

  2. Niraparib treatment for patients with BRCA-mutated ovarian cancer: Review of clinical data and therapeutic context

    Future Oncology, Vol. 18, Núm. 23, pp. 2505-2536

2021

  1. Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial

    The Lancet Oncology, Vol. 22, Núm. 5, pp. 632-642

  2. Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial

    Gynecologic Oncology, Vol. 163, Núm. 1, pp. 41-49

2020

  1. Efficacy of Maintenance Olaparib for Patients with Newly Diagnosed Advanced Ovarian Cancer with a BRCA Mutation: Subgroup Analysis Findings from the SOLO1 Trial

    Journal of Clinical Oncology, Vol. 38, Núm. 30, pp. 3528-3537

  2. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

    Gynecologic Oncology, Vol. 157, Núm. 2, pp. 379-385

2019

  1. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

    Annals of Oncology, Vol. 30, Núm. 7, pp. 1080-1087

  2. Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Obstetrical and Gynecological Survey

2018

  1. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer

    New England Journal of Medicine, Vol. 379, Núm. 26, pp. 2495-2505

  2. Safety and dose modification for patients receiving niraparib

    Annals of Oncology, Vol. 29, Núm. 8, pp. 1784-1792

2017

  1. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

    Obstetrical and Gynecological Survey

  2. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2016

  1. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer

    New England Journal of Medicine, Vol. 375, Núm. 22, pp. 2154-2164

  2. Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer

    International Journal of Cancer, Vol. 139, Núm. 10, pp. 2336-2342

  3. Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): The SOFT-EST substudy

    Journal of Clinical Oncology, Vol. 34, Núm. 14, pp. 1584-1593